Preemptive Rituximab for Epstein–Barr Virus Reactivation After Hematopoietic Cell Transplantation: Necessary for All?
IS reduction as the first-line approach to EBV reactivation was safe and effective in most patients with increasing EBV DNAemia. Consequently, rituximab was required in fewer than 10% of cases.
Authors
- Lilian P. Zanetti
- Mair Pedro de Souza (ORCID: https://orcid.org/0000-0002-7411-9296)
- Leila Cibele S. de Oliveira
- Fernanda Rodrigues Barbieri
- Anderson João Simione (ORCID: https://orcid.org/0000-0002-6939-906X)
- Ariani Impieri de Souza (ORCID: https://orcid.org/0000-0002-7917-5983)
- Élisabeth Delattre
- Juliana Ribeiro do Prado Moreno
- Juliana Silva Santos (ORCID: https://orcid.org/0000-0001-7596-9260)
- Iago Colturato
- Clarisse Martins Machado (ORCID: https://orcid.org/0000-0003-1417-0249)
- Ana Cláudia Ferrari dos Santos (ORCID: https://orcid.org/0000-0002-9999-6316)
- Vergílio A. R. Colturato
Institutions
- Instituto de Medicina Tropical (PY)
- Hospital Amaral Carvalho (BR)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1111/tid.70124
- Citations
- 1
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior